Apellis Pharmaceuticals Inc (NAS:APLS)
$ 40.8801 1.2001 (3.02%) Market Cap: 4.96 Bil Enterprise Value: 4.60 Bil PE Ratio: 0 PB Ratio: 18.58 GF Score: 38/100

Apellis Pharmaceuticals Inc Announces results from Phase 3 DERBY and OAKS Transcript

Sep 09, 2021 / 08:30PM GMT
Release Date Price: $55.61 (+0.05%)
Operator

Good afternoon, everyone, and welcome to the Apellis Pharmaceuticals DERBY and Oaks Top Line Phase III Results Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Meredith Kaya, Senior Vice President of Investor Relations and Strategic Finance at Apellis.

Meredith Kaya
Apellis Pharmaceuticals, Inc. - SVP, IR & Strategic Finance

Good afternoon, and thank you for joining us today to discuss the top line results from the DERBY and OAKS pivotal Phase III studies evaluating pegcetacoplan in patients with geographic atrophy or GA. For those participating via conference call, we have made the slides available via webcast. A replay of this call will also be available on our website following the call.

Before we begin, I would like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot